<DOC>
	<DOCNO>NCT00346125</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , positron emission tomography ( PET ) scan computated tomography ( CT ) scan , may help doctor predict patient 's response treatment may help plan best treatment . Drugs use chemotherapy , doxorubicin ifosfamide , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This clinical trial study well PET scan combine CT scan predicts response patient undergo chemotherapy surgery soft tissue sarcoma .</brief_summary>
	<brief_title>PET CT Predictor Response Preoperative Chemotherapy Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether measurement fludeoxyglucose ( FDG ) positron emission tomography ( PET ) /CT image accurately predict disease-free survival patient soft tissue sarcoma receive neoadjuvant chemotherapy . Secondary - Correlate histological response neoadjuvant chemotherapy soft tissue sarcomas FDG-PET/CT imaging finding . Tertiary - Determine change FDG-PET/CT imaging time course chemotherapy give . OUTLINE : Patients receive 1 2 standard chemotherapy regimen : - Preferred regimen : Patients receive pegylated doxorubicin HCl liposome IV day 1 , ifosfamide IV continuously day 1-6 , pegfilgrastim subcutaneously ( SC ) day 8 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . - Alternative regimen : Patients receive doxorubicin hydrochloride IV continuously day 1-7 . Patients also receive ifosfamide pegfilgrastim preferred regimen . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . All patient undergo fludeoxyglucose positron emission tomography/CT scan baseline , course 1 , completion chemotherapy . Patients undergo surgery within 4-6 week completion chemotherapy . After completion study treatment surgery , patient follow every 6 month 5 year . PROJECTED ACCRUAL : A total 62 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Patients must histologically confirm , high grade , soft tissue sarcoma include malignant fibrous histiocytoma , liposarcoma , fibrosarcoma , leiomyosarcoma , synovial carcinoma , malignant peripheral nerve sheath tumor ( MPNST ) , epithelioid sarcoma , sarcomasnot otherwise specify . NOTE : Ewings sarcoma , primitive neuroectodermal tumor , extraskeletal , osteosarcoma , extraskeletal chondrosarcoma , alveolar soft part sarcoma , rhabdomyosarcoma , carcinosarcoma , Kaposi 's sarcoma , angiosarcoma , mesothelioma patient ineligible study . Measurable disease use traditional cross section measurement primary site 's large diameter &gt; 5 centimeter positron emission tomography/computated tomography ( PET/CT ) , CT magnetic resonance imaging ( MRI ) scan . Patients either localize ( primary locally recurrent ) metastatic disease presentation eligible study receive neoadjuvant treatment prior excision primary ( stage IIC , III , IVA , IVB . ) Age ≥ 16 year , Karnofsky ≥ 70 % Adequate organ function receive chemotherapy determine treat physician . Women childbearing potential sexually active male require use effective method contraception ( ie , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) study . Previous treatment chemotherapy radiation therapy Females know pregnant breastfeeding exclude PET/CT scan pregnant woman FDA approve . Serious concomitant systemic disorder ( eg , active infection ) , opinion investigator , would compromise safety patient compromise patient 's ability complete study . Patients PETCT indicator disease survival soft tissue sarcoma untreated symptomatic CNS metastasis uncontrolled diabetes eligible . Patient must give write informed consent indicate investigational nature study potential risk .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>Malignant fibrous histiocytoma</keyword>
	<keyword>Liposarcoma</keyword>
	<keyword>Fibrosarcoma</keyword>
	<keyword>Leiomyosarcoma</keyword>
	<keyword>Synovial sarcoma</keyword>
	<keyword>Malignant peripheral nerve sheath tumor ( MPNST )</keyword>
	<keyword>Epithelioid sarcoma</keyword>
</DOC>